摘要
静脉输注ＬＡＫ细胞治疗慢乙肝的疗效尚未定论，且乏大样本系统观察。作者以ＬＡＫ输注治疗１９０例慢乙肝，以ＨＢｅＡｇ／ＨＢＶ－ＤＮＡ双阴转率作为评价指标，分别以治疗结束时、结束后３月、１年、２年的双阴转率作为即期、近期、中期与远期疗效，进行观察。与对照组双阴转率（３．３３％）比较，小剂量ＬＡＫ仅具即刻疗效，双阴转率２６．６７％；大、中剂量ＬＡＫ１年期疗效可达２３．３３％与３３．３３％；大剂量ＬＡＫ伍用ｒｈＩＦＮ２年期疗效可达４０％以上。Ｐ均＜０．０５。自体和异体ＬＡＫ疗效无显著差异，Ｐ＞０．０５。本组ＬＡＫ疗法的医源性感染率高达２．１１％，致残率５．２６‰，故作者认为如无良好的实验室条件及训练有素的专业人员，本疗法不宜也不值得广泛开展。
The efficacy of intravenous LAK cells infusion in the treatment of chronic hepatitis B needs further study, and no systemetic & large scale observation has ever been reported.the immediate response rate(just at the end of the treatment),short-term response rate(3 months after the treatment) mediate-term response rate(1 year after the treatment)and long-term response rate (2 years after the treatment)of 190 patients with chronic hepatitis B treated with low middle and large doses of intravenous LAK cells transfusion were studied in our experiment.The effectiveness of this method was shown by both HBeAg and HBV-DNA seroconversion rates. It was 3.33% in controls. The results showed that low doses of LAK cells had only an immediate response rate and the seroconversion rates of both HBeAg and HBV-DNA were 26. 67%,Middle and large doses of LAK cells had a mediate term response rate, with the seroconversion rates of 23.33% and 33. 33%; Large doses of LAK cells combined with recombinent human IFN had a long term response rate, with a seroconversion rate of more than 40%(P<0.05).The efficacy of homogenic and allpgenic LAK cells revealed no significant difference(P>0.05).The incidence of bacterial infection and disable rates resulting from this treatment were as high as 2.11%and 5.26% respectively. So the LAK cells infusion treatment for hepatitis B has very high limitation. It can only be administered by skillful experts in the well-equipped laboratory.
